

K062102

**510(k) Summary**  
**ODONCER Bone Grafting Material**

**Date** March 30, 2007

**Submitter** TEKNIMED, SA  
11 rue Apollo  
31240 L'Union  
FRANCE

APR 16 2007

**Contact person** J.D. Webb  
1001 Oakwood Blvd  
Round Rock, TX 78681  
512-388-0199

**Trade Name** ODONCER

**Common name** Bone Grafting Material

**Classification name** Bone grafting material for dental bone repair  
Class II per 21 CFR section 888.3045

**Product Code** LPK

**Equivalent Device** OSSAPLAST Dental (K053374) (OssascurAG)  
CALC-I-OSS (K042583) (Ultradent Products)  
Cerasob M Dental (K051443) (Curasan AG)

**Device Description**

ODONCER is an osseo-conductive powder implant made of synthetic beta tricalcium phosphate ( $\beta$ -TCP ( $\text{Ca}_3(\text{PO}_4)_2$ ) indicated for bone grafting in dental applications.

**Intended Use**

ODONCER Bone Grafting Material is recommended for:

- Augmentation or reconstructive treatment of the alveolar ridge.
- Filling of infrabony periodontal defects.
- Filling of defects after root resection, apicoectomy, and cystectomy.
- Filling of extraction sockets to enhance preservation of the alveolar ridge.
- Elevation of the maxillary sinus floor.
- Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration and Guided Bone Regeneration.
- Filling of perio-implant defects in conjunction with products intended for Guided Bone Regeneration.

**Summary Nonclinical Tests**

ODONCER does not incorporate any new technological characteristics as compared to the predicate devices. ODONCER and the predicate devices are made from the same material (pure-phase P-TCP) and conform to the standard specifications of ASTM F1088-04 for a medical grade  $\beta$ -TCP to be used in surgical implant applications. ODONCER is substantially equivalent to the predicate devices in regard to structure, porosity, form, packaging, sterility, and biocompatibility.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

SEP 13 2007

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Teknimed SA  
C/O Mr. J.D. Webb  
1001 Oakwood Boulevard  
Round Rock, Texas 78681

Re: K062102  
Trade/Device Name: ODONCER Bone Grafting Material  
Regulation Number: 21 CFR 872.3930  
Regulation Name: Bone Grafting Material  
Regulatory Class: II  
Product Code: LYC  
Dated: March 30, 2007  
Received: April 2, 2007

Dear Mr. Webb:

This letter corrects our substantially equivalent letter of April 16, 2007.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115 (<http://www.fda.gov/cdrh/organiz.html#OC> for OC organization structure). Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Chiu Lin', with a stylized flourish at the end.

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,  
Infection Control and Dental Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (If known):

Device Name: ODONCER Bone Grafting Material

### Indications for Use:

ODONCER Bone Grafting Material is recommended for:

- Augmentation or reconstructive treatment of the alveolar ridge.
- Filling of infrabony periodontal defects.
- Filling of defects after root resection, apicoectomy, and cystectomy.
- Filling of extraction sockets to enhance preservation of the alveolar ridge.
- Elevation of the maxillary sinus floor.
- Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration and Guided Bone Regeneration.
- Filling of perio-implant defects in conjunction with products intended for Guided Bone Regeneration.

Prescription Use X  
Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF  
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1



Chief of Anesthesiology, General Hospital,  
Device Control, Dental Devices

510(k) Number: K062102